What are the key takeaways for Johnson & Johnson ($JNJ)?

Johnson & Johnson reported Q3 2026 revenue of $25,399 million, representing a 5.9% YoY increase driven by balanced growth across Innovative Medicine and MedTech. Quarterly net income stood at $210 million with diluted EPS of $0.09, reflecting period-specific legal provisions and ongoing litigation management. Operating cash flow remained exceptionally strong at $7,720 million, supported by robust free cash flow generation of $6,358 million.

Johnson & Johnson (JNJ) AI Stock Analysis & Earnings

Please enable JavaScript to continue using this application.

Overview Charts AI Summary Financials Valuation

Based on September 27, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Johnson & Johnson ($JNJ)

Johnson & Johnson (JNJ) reported For the quarterly period ended September 27, 2026 (Issuer fiscal Q3 FY2026) revenue of $25,399 million with diluted EPS of $0.09 and net income of $210 million. Pretax margin was 0.1%, as $5,780 million of other expense (net) cut pretax income to $34 million, and free cash flow was $6,358 million for the period. Management commentary emphasized steady execution across both Innovative Medicine and MedTech segments, driven by strong uptake in oncology therapies and cardiovascular medical devices. Research and development investments reached $4,652 million during the quarter, underscoring ongoing commitment to pipeline expansion and advanced technological integration. The balance sheet remains solid with $16,910 million in cash and cash equivalents against $44,651 million in debt, providing ample liquidity to navigate litigation contingencies and fund strategic growth initiatives.

Key Takeaways

1.Johnson & Johnson reported Q3 2026 revenue of $25,399 million, representing a 5.9% YoY increase driven by balanced growth across Innovative Medicine and MedTech.
2.Quarterly net income stood at $210 million with diluted EPS of $0.09, reflecting period-specific legal provisions and ongoing litigation management.
3.Operating cash flow remained exceptionally strong at $7,720 million, supported by robust free cash flow generation of $6,358 million.
4.Research and development investment totaled $4,652 million, reinforcing the company's commitment to advancing its pharmaceutical and medtech pipelines.
5.The balance sheet maintains solid liquidity with $16,910 million in cash against $44,651 million in total debt, maintaining financial flexibility.
6.MedTech and Innovative Medicine segments continue to benefit from new product introductions and expanding global healthcare demand.

What They Do

Johnson & Johnson is a preeminent global healthcare enterprise engaged in the research, development, manufacture, and sale of a broad range of products in the health care field. The company operates through two major business segments: Innovative Medicine (focusing on immunology, oncology, neuroscience, cardiovascular, and metabolic diseases) and MedTech (encompassing orthopedic, surgical, cardiovascular, and vision solutions). Customers include hospitals, clinics, managed care organizations, and individual healthcare practitioners across global markets.

How They Make Money

The company generates revenue primarily through the sale of pharmaceutical products and medical devices to distributors, wholesalers, hospitals, and healthcare professionals worldwide. Revenue is recognized when control of the product transfers to the customer, typically upon delivery. The revenue model relies on high-volume product sales backed by strong intellectual property protection, proprietary drug formulations, and entrenched medical device systems. Growth is driven by volume expansion, new product launches, strategic pricing actions, and targeted acquisitions within high-value therapeutic and procedural areas.

Competitive Position

Johnson & Johnson competes against major global pharmaceutical and medical technology giants such as Pfizer, Roche, Novartis, Merck, and Medtronic. The company's competitive advantages stem from massive global scale, established brand trust among medical professionals, deep regulatory expertise, and an extensive intellectual property portfolio. Relative to peers, JNJ maintains premium gross margins (approximately 68%) and strong cash flow conversion, though it faces ongoing margin headwinds from litigation and competitive generic/biosimilar pressures. Financial trends indicate stable market share expansion in specialized oncology and cardiovascular segments.

Business Strategy & Moat

Johnson & Johnson's strategic framework centers on strengthening its competitive moat through proprietary scientific innovation, targeted portfolio shaping, and operational excellence. The moat is anchored by durable intellectual property in pharmaceuticals and high switching costs within entrenched MedTech hospital workflows. Capital allocation strategy prioritizes heavy R&D reinvestment, consistent dividend growth, selective value-accretive M&A, and opportunistic share repurchases. Financial metrics, including high average ROIC and robust cash generation, validate the durability of this strategic model.

Industry Outlook

The global healthcare sector benefits from secular tailwinds including aging populations, increasing chronic disease prevalence, and expanding healthcare access in emerging economies. Near-term headwinds include inflationary cost pressures, pricing scrutiny from governments and payors, and patent expirations on legacy pharmaceutical blockbusters. The regulatory landscape remains stringent, requiring significant compliance investment while favoring well-capitalized incumbents with robust clinical trial infrastructure.

Growth Drivers

•Continued market penetration and label expansions for key oncology and immunology blockbuster therapies.
•New product launches and technological innovations within the MedTech cardiovascular and surgical portfolios.
•Strategic geographic expansion across emerging healthcare markets with rising middle-class healthcare expenditures.
•Targeted business development and bolt-on acquisitions adding complementary technological capabilities.
•Accelerated digital and AI-driven enhancements in clinical trial design and supply chain optimization.

Recent Developments

•Advanced ongoing legal negotiations and settlement frameworks regarding talc-related litigation liabilities.
•Continued commercial rollout of recently acquired medical technology platforms in cardiovascular and surgical intervention.
•Announced ongoing pipeline advancements and regulatory submissions across major Innovative Medicine therapeutic areas.
•Maintained disciplined capital allocation through ongoing quarterly dividend distributions and share repurchase executions.

Catalysts

•Upcoming pivotal clinical trial readouts across late-stage Innovative Medicine pipeline assets through 2026.
•Regulatory decisions and FDA approvals for new drug applications and medical device line extensions.
•Definitive legal resolutions or settlement milestones concerning outstanding talc litigation matters.
•Quarterly financial disclosures demonstrating continued margin stability and cash flow conversion.

Acquisitions & Strategy

•Acquired Abiomed in recent periods to significantly expand leadership in the high-growth cardiovascular intervention medtech space.

Share Repurchase / Buyback Program

•Executed common stock repurchases totaling $1,709,000,000 in Q3 2026, bringing nine-month repurchases to $5,958,000,000, alongside ongoing capital return commitments authorized by the board.

RPO & Key Performance Indicators

•Maintained strong operating cash flow generation exceeding $7.7 billion in the latest reported quarter, demonstrating underlying cash conversion efficiency.

Strengths

•Diversified business model spanning both Innovative Medicine and MedTech, mitigating single-segment concentration risks.
•Exceptional gross margin profile averaging over 67% supported by differentiated proprietary products.
•Robust cash flow generation with TTM free cash flow exceeding $20.5 billion.
•Strong balance sheet liquidity with $16.9 billion in cash and cash equivalents.
•Extensive global commercial reach and established relationships with healthcare providers worldwide.

AI Benefits & Opportunities

•Integration of artificial intelligence and machine learning to accelerate drug discovery pipelines and optimize clinical trial patient recruitment.
•Operational efficiency gains across global manufacturing supply chains and inventory management through predictive analytics.

Risks & Concerns for Johnson & Johnson ($JNJ)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

AI-generated research for Johnson & Johnson (JNJ, filings period ending September 27, 2026). AI summaries, reports, and scoring can be inaccurate or incorrect; accuracy and correctness are not guaranteed. Informational only; not investment advice or personalized guidance.Enumerated risk factors in this view may be abbreviated for anonymous or guest sessions. Full risk sections are available with full access.

Summary generated on Oct 23, 2026.

Peers of Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) AI Stock Analysis & Earnings

Based on September 27, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Johnson & Johnson ($JNJ)

Key Takeaways

1.Johnson & Johnson reported Q3 2026 revenue of $25,399 million, representing a 5.9% YoY increase driven by balanced growth across Innovative Medicine and MedTech.
2.Quarterly net income stood at $210 million with diluted EPS of $0.09, reflecting period-specific legal provisions and ongoing litigation management.
3.Operating cash flow remained exceptionally strong at $7,720 million, supported by robust free cash flow generation of $6,358 million.
4.Research and development investment totaled $4,652 million, reinforcing the company's commitment to advancing its pharmaceutical and medtech pipelines.
5.The balance sheet maintains solid liquidity with $16,910 million in cash against $44,651 million in total debt, maintaining financial flexibility.
6.MedTech and Innovative Medicine segments continue to benefit from new product introductions and expanding global healthcare demand.

What They Do

How They Make Money

Competitive Position

Business Strategy & Moat

Industry Outlook

Growth Drivers

•Continued market penetration and label expansions for key oncology and immunology blockbuster therapies.
•New product launches and technological innovations within the MedTech cardiovascular and surgical portfolios.
•Strategic geographic expansion across emerging healthcare markets with rising middle-class healthcare expenditures.
•Targeted business development and bolt-on acquisitions adding complementary technological capabilities.
•Accelerated digital and AI-driven enhancements in clinical trial design and supply chain optimization.

Recent Developments

•Advanced ongoing legal negotiations and settlement frameworks regarding talc-related litigation liabilities.
•Continued commercial rollout of recently acquired medical technology platforms in cardiovascular and surgical intervention.
•Announced ongoing pipeline advancements and regulatory submissions across major Innovative Medicine therapeutic areas.
•Maintained disciplined capital allocation through ongoing quarterly dividend distributions and share repurchase executions.

Catalysts

•Upcoming pivotal clinical trial readouts across late-stage Innovative Medicine pipeline assets through 2026.
•Regulatory decisions and FDA approvals for new drug applications and medical device line extensions.
•Definitive legal resolutions or settlement milestones concerning outstanding talc litigation matters.
•Quarterly financial disclosures demonstrating continued margin stability and cash flow conversion.

Acquisitions & Strategy

•Acquired Abiomed in recent periods to significantly expand leadership in the high-growth cardiovascular intervention medtech space.

Share Repurchase / Buyback Program

•Executed common stock repurchases totaling $1,709,000,000 in Q3 2026, bringing nine-month repurchases to $5,958,000,000, alongside ongoing capital return commitments authorized by the board.

RPO & Key Performance Indicators

•Maintained strong operating cash flow generation exceeding $7.7 billion in the latest reported quarter, demonstrating underlying cash conversion efficiency.

Strengths

•Diversified business model spanning both Innovative Medicine and MedTech, mitigating single-segment concentration risks.
•Exceptional gross margin profile averaging over 67% supported by differentiated proprietary products.
•Robust cash flow generation with TTM free cash flow exceeding $20.5 billion.
•Strong balance sheet liquidity with $16.9 billion in cash and cash equivalents.
•Extensive global commercial reach and established relationships with healthcare providers worldwide.

AI Benefits & Opportunities

•Integration of artificial intelligence and machine learning to accelerate drug discovery pipelines and optimize clinical trial patient recruitment.
•Operational efficiency gains across global manufacturing supply chains and inventory management through predictive analytics.

Risks & Concerns for Johnson & Johnson ($JNJ)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

Summary generated on Oct 23, 2026.

Latest Report Overview for Johnson & Johnson ($JNJ)

AI-powered analysis of Johnson & Johnson (JNJ) stock based on Q3 2026 financial data.

Published: October 23, 2026

Latest Report Overview

Key Takeaways for Johnson & Johnson

Johnson & Johnson reported Q3 2026 revenue of $25,399 million, representing a 5.9% YoY increase driven by balanced growth across Innovative Medicine and MedTech.
Quarterly net income stood at $210 million with diluted EPS of $0.09, reflecting period-specific legal provisions and ongoing litigation management.
Operating cash flow remained exceptionally strong at $7,720 million, supported by robust free cash flow generation of $6,358 million.
Research and development investment totaled $4,652 million, reinforcing the company's commitment to advancing its pharmaceutical and medtech pipelines.
The balance sheet maintains solid liquidity with $16,910 million in cash against $44,651 million in total debt, maintaining financial flexibility.
MedTech and Innovative Medicine segments continue to benefit from new product introductions and expanding global healthcare demand.

What Does Johnson & Johnson Do?

Growth Drivers for Johnson & Johnson

Continued market penetration and label expansions for key oncology and immunology blockbuster therapies.